Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.
TAG, as part of the Save NY Public Health Campaign, called out Governor Cuomo's recently announced Medicaid cuts and other failures to adequately address health and health equity in his January 8, 2020 "State of the State" address.
TAG’s work in 2019 demonstrated our leadership towards an end to HIV, hepatitis C, and tuberculosis through hard-hitting, science-based activism. Excerpts of the media coverage we received walk you through a remarkable year of TAG’s work.
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2018 and analyzes trends in funding since 2005.
Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.
Vote Your ConSCIENCE: Elevating Health Justice in the 2020 Elections. 2020 marks the eighth U.S. presidential election cycle since Treatment Action Group’s founding in 1992. A hallmark of our activism has been to prepare for each presidential and congressional election cycle strategically, to ensure that whoever is elected, and whoever controls the House and the Senate, is informed about the best scientifically grounded research and policy and research programs.
To encourage more equitable access to new and repurposed TB drugs, TAG signed on to letters of support for the inclusion of rifapentine, bedaquiline, delamanid, and linezolid on the WHO's Model List of Essential Medicines. The 20th Expert Committee on the Selection and Use of Essential Medicines will review drug applications and public comments in April 2015.